Literature DB >> 12650608

Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.

Michael S Kinch1, Kelly Carles-Kinch.   

Abstract

Cancer is a disease of aberrant signal transduction. The expression and function of intracellular signaling pathways are frequently subverted as cells progress towards a metastatic phenotype. In particular, tyrosine kinases initiate powerful signals that govern many different aspects of cell behavior. In Recent studies have demonstrated that the EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in aggressive tumor cells, and that these changes promote metastatic character. Herein, we provide an overview of our current understanding of EphA2, with emphasis upon the differential regulation of EphA2 expression and function. We also show that differential EphA2 expression and function may provide a unique opportunity for selective therapeutic targeting of EphA2 in metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650608     DOI: 10.1023/a:1022546620495

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  88 in total

Review 1.  The Eph family of receptors.

Authors:  E B Pasquale
Journal:  Curr Opin Cell Biol       Date:  1997-10       Impact factor: 8.382

Review 2.  Fibronectin and its integrin receptors in cancer.

Authors:  E Ruoslahti
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

Review 3.  Altered adhesions in ras-transformed breast epithelial cells.

Authors:  M S Kinch; K Burridge
Journal:  Biochem Soc Trans       Date:  1995-08       Impact factor: 5.407

Review 4.  Epithelial-mesenchymal transitions in cancer progression.

Authors:  C Birchmeier; W Birchmeier; B Brand-Saberi
Journal:  Acta Anat (Basel)       Date:  1996

5.  MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer.

Authors:  N D Zantek; J Walker-Daniels; J Stewart; R K Hansen; D Robinson; H Miao; B Wang; H J Kung; M J Bissell; M S Kinch
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

6.  Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase.

Authors:  A Pandey; H Duan; V M Dixit
Journal:  J Biol Chem       Date:  1995-08-18       Impact factor: 5.157

7.  Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium.

Authors:  G Berclaz; A C Andres; D Albrecht; E Dreher; A Ziemiecki; B A Gusterson; M R Crompton
Journal:  Biochem Biophys Res Commun       Date:  1996-09-24       Impact factor: 3.575

8.  Phosphotyrosine-containing proteins are concentrated in differentiating cells during chicken embryonic development.

Authors:  G Patstone; P A Maher
Journal:  Growth Factors       Date:  1993       Impact factor: 2.511

9.  Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia.

Authors:  M S Kinch; G J Clark; C J Der; K Burridge
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

10.  Integrin-mediated signals regulated by members of the rho family of GTPases.

Authors:  E A Clark; W G King; J S Brugge; M Symons; R O Hynes
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539

View more
  58 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells.

Authors:  Aurelie Borrull; Stephanie Ghislin; Frederique Deshayes; Jessica Lauriol; Catherine Alcaide-Loridan; Sandrine Middendorp
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-11       Impact factor: 4.553

3.  Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase.

Authors:  David Vaught; Jin Chen; Dana M Brantley-Sieders
Journal:  Mol Biol Cell       Date:  2009-03-25       Impact factor: 4.138

4.  EphA2 as a new target for breast cancer and its potential clinical application.

Authors:  Lingzhi Zhou; Xuejing Lu; Bensi Zhang; Yaqi Shi; Zhuang Li
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

5.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

Authors:  Manabu Hatano; Junichi Eguchi; Tomohide Tatsumi; Naruo Kuwashima; Jill E Dusak; Michel S Kinch; Ian F Pollack; Ronald L Hamilton; Walter J Storkus; Hideho Okada
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

6.  Specificity of HCPTP variants toward EphA2 tyrosines by quantitative selected reaction monitoring.

Authors:  Deepa Balasubramaniam; Lake N Paul; Kristoff T Homan; Mark C Hall; Cynthia V Stauffacher
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 8.  The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.

Authors:  Irina Alho; Luís Costa; Manuel Bicho; Constança Coelho
Journal:  Tumour Biol       Date:  2013-04-14

9.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

10.  EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.

Authors:  Elisa Giannoni; Maria Letizia Taddei; Matteo Parri; Francesca Bianchini; Michela Santosuosso; Renata Grifantini; Gabriella Fibbi; Benedetta Mazzanti; Lido Calorini; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2012-08-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.